How does the Raman spectrum of tumor microenvironments differ from that of normal tissues?5 answersThe Raman spectrum of tumor microenvironments differs from that of normal tissues due to distinct biomolecular changes. Tumors exhibit significant alterations in lipid and collagen content post-radiation, with greater changes in radiation-sensitive tumors. In breast cancer, a transition from monounsaturated fatty acids to polyunsaturated fatty acids was observed in tumors, highlighting macroenvironmental effects on cancer progression. Additionally, Raman spectroscopy can differentiate biochemical compounds in normal brain tissue from various tumors, such as glioblastoma and meningioma, with high discrimination accuracy. This technique provides valuable diagnostic information for in situ cancer detection and label-free histopathology, offering insights into both cancer cells and their microenvironment.
What is the difference in dielectric properties of normal cell and cancerous cell in human body?4 answersThe dielectric properties of normal cells and cancerous cells in the human body differ in terms of electrical conductivity, relative permittivity, and capacitance. Cancerous cells generally have higher electrical conductivity and lower relative permittivity compared to normal cells. This difference in dielectric properties is attributed to factors such as higher water content and electrolyte concentration in cancerous tissues, as well as changes in physiological and biochemical properties. Additionally, the relaxation frequency, which correlates with the dielectric loss factor, is found to be higher in cancer cells compared to healthy cells. These variations in dielectric properties provide the basis for distinguishing between normal and cancerous cells, and can be utilized for cancer diagnosis and prognosis follow-up.
What are the different types of breast cancer cell lines?5 answersBreast cancer cell lines can be classified into different types based on their molecular subtypes. These subtypes include luminal A and B cells, which are estrogen receptor (ER) and/or progesterone receptor (PR) positive, HER2-enriched cells, which exhibit an overexpression of the HER2 oncogene, and triple-negative cells, which are negative for ER, PR, and HER2 expression. Some specific breast cancer cell lines that have been studied include MACL-1 and MGSO-3, which were derived from luminal A subtype carcinoma and ductal carcinoma in situ, respectively, but lost the expression of these markers over cell culturing and now have a triple-negative phenotype. Other breast cancer cell lines include MCF-10A, a normal epithelial cell line, and MDA-MB-231, a well-established metastatic-derived breast cancer cell line. Additionally, there are several other breast cancer cell lines that have been established from primary carcinomas, pleural effusion, pericardial effusion, and ascitic fluid samples obtained from breast carcinoma patients.
How to tune optical properties of tumors?3 answersThe optical properties of tumors can be tuned through various methods. One approach is to use near infrared light, which has better light penetrance compared to other wavelengths, to activate photosensitizers for photodynamic therapy. Another method involves injecting absorption-enhancement dyes into tumors and using oblique-incidence reflectometry to measure and model the optical properties. This allows for optimal delivery of light into the tumor while minimizing damage to normal tissue. Additionally, the use of plasmon-resonant nanoparticles and NIR laser irradiation has been shown to decrease the absorption and scattering properties of tumors, resulting in changes to their optical properties. In the case of pigmented skin tumors, oblique incidence diffuse reflectance spectroscopy has been used to estimate the optical properties and differentiate between malignant, dysplastic, and benign lesions. Finally, the optical properties of brain tumors have been found to differ from normal brain tissue, with higher levels of absorption and deeper penetration in the near infrared spectral range.
Which nanoparticles are used for bioimaging in breast cancer?5 answersNanoparticles used for bioimaging in breast cancer include I2-IR783/MTX@NPs, lipid polymer hybrid nanoparticles, inorganic hybrid nanoparticles, metal-organic hybrid nanoparticles, and hybrid carbon nanocarriers, and human red blood cell (RBC) membrane-coated polymeric nanoparticles (TT-RBC-NPs). Poly(lactic-co-glycolic acid)-based polymer nanoparticles loaded with photosensitizers are also used for phototherapy of breast tumors. These nanoparticles offer advantages such as enhanced targeting functionality, improved structural and biological properties, and prolonged circulation time. They can specifically bind to targeted cancer cells, deliver therapeutic agents, visualize cancer cells, and achieve enhanced cytotoxic efficacy against breast cancer cells. Nanotheranostic carriers, including ligand-targeted nanocarriers, are being explored for imaging and therapeutic applications in breast cancer.
What are the different types of human breast cancer cells?2 answersBreast cancers are complex cellular ecosystems with diverse types of malignancies. Invasive ductal cancer is the most common type, followed by invasive lobular, tubular, cancer in a cyst, mucous, medullary, and other types. There are also special histologic features in breast cancers, including mucinous carcinoma, secretory carcinoma, invasive micropapillary carcinoma, mammary neuroendocrine carcinoma, cystic hypersecretory carcinoma, glycogen-rich clear cell carcinoma, and carcinoma with osteoclast-like giant cells. Additionally, breast tumors can consist of multiple types of malignancies, such as squamous cell carcinoma, invasive ductal carcinoma, and high-grade breast sarcoma. Transformation of different cell types in the breast can give rise to various forms of breast cancer, including luminal and basal-like tumors from EpCAM+ epithelial cells and metaplastic tumors from CD10+ cells.